Aquaro Histology, Inc.

Aquaro Histology, Inc. develops advanced histology solutions that enhance the efficiency of tissue analysis and pathology services, catering primarily to healthcare and research sectors. Founded in 2014 and headquartered in Ann Arbor, US, Aquaro Histology, Inc. specializes in providing innovative histology services.

The company has undergone no significant pivots and does not have known subsidiaries. Its latest funding round was a Series A, where it raised USD 9. 8 mn led by Telegraph Hill Partners on November 2, 2017, bringing the total amount raised to USD 9. 8 mn.

Aquaro Histology, Inc. primarily offers advanced histology solutions designed to enhance tissue analysis and pathology services. Their core offerings include a suite of tools that streamline the process of slide preparation, imaging, and data analysis for medical and research institutions. Their clients include hospitals, research laboratories, and educational institutions, particularly in the North American and European markets, who utilize these services to improve workflow efficiency and accuracy in histological studies.

The company operates on a subscription-based revenue model, where clients pay a recurring fee for access to their histology services and tools. These agreements typically involve annual or monthly contracts that allow clients to utilize Aquaro’s platform for their histological needs. Additionally, tiered pricing plans are available that include varying levels of service and support, catering to the specific operational requirements of their diverse clientele. This structure ensures a stable cash flow, supported by a growing base of customers in targeted regions.

Aquaro Histology, Inc. plans to leverage its recent funding from the Series A round to further develop its histology solutions and expand its market presence. The company is focused on introducing new products designed to enhance tissue analysis capabilities, with expected launches in the coming year. Additionally, Aquaro aims to penetrate new geographical regions, specifically targeting the Asian markets by 2025, to capitalize on the growing demand for advanced histological services.

The recent investment will support product development and market entry initiatives.